brigimadlin: Clinical Trials

11 trials of brigimadlin, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

8 completed, 2 withdrawn, 1 active not recruiting. 5 Phase 1, 4 Phase 2, 3 Phase 3.

By phase and status

Phase	Trials	Status
Phase 1	5	Completed 5
Phase 2	4	Completed 2, Active not recruiting 1, Withdrawn 1
Phase 3	3	Completed 2, Withdrawn 1

Follow brigimadlin: new trials by email Literature Review of brigimadlin trials Research Report on brigimadlin

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine Brigimadlin - Solid Tumours	Phase 2	Active not recruiting	Boehringer Ingelheim	90	2024-12-30	2026-09-29
Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma Brigimadlin, Ezabenlimab, Gemcitabine - Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS)	Phase 3	Withdrawn	Boehringer Ingelheim		2024-06-27	2024-07-17
Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures Ezabenlimab + BI907828 - Adult Soft Tissue Sarcoma, Non Small Cell Lung Cancer	Phase 2	Withdrawn	Institut Bergonié		2024-06-14	2025-09-02
Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma Brigimadlin - Liposarcoma, Dedifferentiated	Phase 3	Completed	Boehringer Ingelheim	138	2023-12-13	2026-01-09
A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body [¹⁴C]-BI 907828 mixed with BI 907828 (formulation 1), [¹⁴C]-BI 907828 mixed with BI 907828 (formulation 2), BI 907828 - Solid Tumors	Phase 1	Completed	Boehringer Ingelheim	13	2023-01-03	2025-01-22
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder Brigimadlin - Pancreatic Neoplasms, Solid Tumors	Phase 2	Completed	Boehringer Ingelheim	99	2022-12-13	2026-10-14
A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma BI 907828 (Brigimadlin) - Glioblastoma	Phase 1	Completed	Boehringer Ingelheim	24	2022-11-30	2025-08-24
A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor BI 907828, Rifampicin, Itraconazole - Solid Tumors	Phase 1	Completed	Boehringer Ingelheim	33	2022-08-11	2026-02-03
Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma Brigimadlin, Doxorubicin - Liposarcoma, Dedifferentiated	Phase 2 / Phase 3	Completed	Boehringer Ingelheim	400	2022-03-31	2026-03-02
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) BI 907828, ezabenlimab, BI 754111 - Neoplasms	Phase 1	Completed	Boehringer Ingelheim	119	2019-06-20	2026-02-18
This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) BI 907828 - Neoplasms	Phase 1	Completed	Boehringer Ingelheim	266	2018-06-20	2026-03-31

Conditions studied

Sponsors

Countries

Results publications

NIH funding